Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
Record number 425222
Title Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity
Author(s) Tacken, P.J.; Zeelenberg, I.S.; Cruz, L.J.; Hout-Kuijer, M.A.; Glind, G. van de; Fokkink, R.G.; Lambeck, A.J.A.; Figdor, C.G.
Source Blood : journal of the American Society of Hematology 118 (2011)26. - ISSN 0006-4971 - p. 6836 - 6844.
Department(s) Physical Chemistry and Colloid Science
Publication type Refereed Article in a scientific journal
Publication year 2011
Keyword(s) tumor-necrosis-factor - in-vivo - cross-presentation - polyribocytidylic acid - antigen presentation - t-cells - receptor - activation - responses - immunity
Abstract Effective vaccines consist of 2 components: immunodominant antigens and effective adjuvants. Whereas it has been demonstrated that targeted delivery of antigens to dendritic cells (DCs) improves vaccine efficacy, we report here that co-targeting of TLR ligands (TLRLs) to DCs strongly enhances adjuvanticity and immunity. We encapsulated ligands for intracellular TLRs within biodegradable nanoparticles coated with Abs recognizing DC-specific receptors. Targeted delivery of TLRLs to human DCs enhanced the maturation and production of immune stimulatory cytokines and the Ag-specific activation of naive CD8(+) T cells. In vivo studies demonstrated that nanoparticles carrying Ag induced cytotoxic T-lymphocyte responses at 100-fold lower adjuvant dose when TLRLs were co-encapsulated instead of administered in soluble form. Moreover, the efficacy of these targeted TLRLs reduced the serum cytokine storm and related toxicity that is associated with administration of soluble TLRLs. We conclude that the targeted delivery of adjuvants may improve the efficacy and safety of DC-based vaccines. (Blood.2011;118(26):6836-6844)
There are no comments yet. You can post the first one!
Post a comment
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.